HOSPITAL MEDICINES LIST
RESTRICTIONS CHECKLIST

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER

Name: .....

Ward: .....

PATIENT:

Name: .....

NHI: .....

Casirivimab and imdevimab

INITIATION – Treatment of profoundly immunocompromised patients
Re-assessment required after 2 weeks
Prerequisites (tick boxes where appropriate)

- ○ Patient has confirmed (or probable) COVID-19

and

- ○ The patient is in the community (treated as an outpatient) with mild to moderate disease severity*

and

- ○ Patient is profoundly immunocompromised** and is at risk of not having mounted an adequate response to vaccination against COVID-19 or is unvaccinated

and

- ○ Patient's symptoms started within the last 10 days

and

- ○ Patient is not receiving high flow oxygen or assisted/mechanical ventilation

and

- ○ Casirivimab and imdevimab is to be administered at a maximum dose of no greater than 2,400 mg

Note: * Mild to moderate disease severity as described on the Ministry of Health Website
** Examples include B-cell depletive illnesses or patients receiving treatment that is B-Cell depleting.

INITIATION – mild to moderate COVID-19-hospitalised patients
Re-assessment required after 2 weeks
Prerequisites (tick boxes where appropriate)

- ○ Prescribed by, or recommended by any relevant practitioner, or in accordance with a protocol or guideline that has been endorsed by the Te Whatu Ora Hospital.

and

- ○ Patient has confirmed (or probable) COVID-19

and

- ○ Patient is an in-patient in hospital with mild to moderate disease severity*

and

- ○ Patient's symptoms started within the last 10 days

and

- ○ Patient is not receiving high flow oxygen or assisted/mechanical ventilation

and

- ○ Age > 50

or

- ○ BMI > 30

or

- ○ Patient is Māori or Pacific ethnicity

or

- ○ Patient is at increased risk of severe illness from COVID-19, excluding pregnancy, as described on the Ministry of Health website (see Notes)

and

- ○ Patient is unvaccinated

or

- ○ Patient is seronegative where serology testing is readily available or strongly suspected to be seronegative where serology testing is not available

and

- ○ Casirivimab and imdevimab is to be administered at a maximum dose of no greater than 2,400 mg

Note: * Mild to moderate disease severity as described on the Ministry of Health Website
**(https://www.health.govt.nz/our-work/diseases-and-conditions/covid-19-novel-coronavirus/covid-19-information-specific-audiences/covid-19-advice-higher-risk-people)

I confirm that the above details are correct:

Signed: ..... Date: .....